MXPA06012380A - Compuestos como antagonistas de receptor de quimiocina 1 (ccr-1). - Google Patents
Compuestos como antagonistas de receptor de quimiocina 1 (ccr-1).Info
- Publication number
- MXPA06012380A MXPA06012380A MXPA06012380A MXPA06012380A MXPA06012380A MX PA06012380 A MXPA06012380 A MX PA06012380A MX PA06012380 A MXPA06012380 A MX PA06012380A MX PA06012380 A MXPA06012380 A MX PA06012380A MX PA06012380 A MXPA06012380 A MX PA06012380A
- Authority
- MX
- Mexico
- Prior art keywords
- chloro
- fluorobenzyl
- carbon atoms
- compound
- phenyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 368
- 239000005557 antagonist Substances 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 claims abstract description 22
- 150000002148 esters Chemical class 0.000 claims abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 10
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 201000010099 disease Diseases 0.000 claims abstract description 9
- -1 nitro, oxy Chemical group 0.000 claims description 221
- 125000004432 carbon atom Chemical group C* 0.000 claims description 67
- 125000001424 substituent group Chemical group 0.000 claims description 58
- 125000000217 alkyl group Chemical group 0.000 claims description 39
- 229910052739 hydrogen Inorganic materials 0.000 claims description 37
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 32
- 125000000304 alkynyl group Chemical group 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 31
- 125000003342 alkenyl group Chemical group 0.000 claims description 30
- 239000001257 hydrogen Substances 0.000 claims description 30
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 30
- PSDYQSWHANEKRV-UHFFFAOYSA-N [S]N Chemical compound [S]N PSDYQSWHANEKRV-UHFFFAOYSA-N 0.000 claims description 28
- 125000003118 aryl group Chemical group 0.000 claims description 27
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 26
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 24
- 125000001072 heteroaryl group Chemical group 0.000 claims description 23
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 claims description 20
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 20
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 20
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims description 19
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 18
- 125000004043 oxo group Chemical group O=* 0.000 claims description 18
- 239000000460 chlorine Substances 0.000 claims description 17
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 13
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 12
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 11
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 11
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 11
- 125000001624 naphthyl group Chemical group 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 9
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 7
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 7
- 230000001363 autoimmune Effects 0.000 claims description 7
- 239000003018 immunosuppressive agent Substances 0.000 claims description 7
- 101100515517 Arabidopsis thaliana XI-I gene Proteins 0.000 claims description 6
- 125000002252 acyl group Chemical group 0.000 claims description 6
- 150000001408 amides Chemical class 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 229910052740 iodine Inorganic materials 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 238000002610 neuroimaging Methods 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 206010061218 Inflammation Diseases 0.000 claims description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- 238000003745 diagnosis Methods 0.000 claims description 5
- 230000004054 inflammatory process Effects 0.000 claims description 5
- 239000003550 marker Substances 0.000 claims description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 4
- 230000001506 immunosuppresive effect Effects 0.000 claims description 4
- 229940125721 immunosuppressive agent Drugs 0.000 claims description 4
- 230000009467 reduction Effects 0.000 claims description 4
- 102000009410 Chemokine receptor Human genes 0.000 claims description 3
- 108050000299 Chemokine receptor Proteins 0.000 claims description 3
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical class NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- 125000002619 bicyclic group Chemical group 0.000 claims description 3
- 239000003054 catalyst Substances 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 230000004968 inflammatory condition Effects 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 229940127557 pharmaceutical product Drugs 0.000 claims description 3
- 229940124530 sulfonamide Drugs 0.000 claims description 3
- 150000003456 sulfonamides Chemical class 0.000 claims description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- 239000007822 coupling agent Substances 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 229910052763 palladium Inorganic materials 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 13
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 3
- 125000000547 substituted alkyl group Chemical group 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 abstract description 6
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 abstract description 5
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 abstract description 5
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 description 280
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 261
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 241
- 238000005160 1H NMR spectroscopy Methods 0.000 description 232
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 217
- 238000004587 chromatography analysis Methods 0.000 description 190
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 184
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 178
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 160
- 239000013078 crystal Substances 0.000 description 151
- 229910052681 coesite Inorganic materials 0.000 description 133
- 229910052906 cristobalite Inorganic materials 0.000 description 133
- 229910052682 stishovite Inorganic materials 0.000 description 133
- 229910052905 tridymite Inorganic materials 0.000 description 133
- 239000000047 product Substances 0.000 description 127
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 84
- 239000011541 reaction mixture Substances 0.000 description 78
- 239000011734 sodium Substances 0.000 description 78
- 239000006260 foam Substances 0.000 description 77
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 76
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 75
- 239000012074 organic phase Substances 0.000 description 67
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 63
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 61
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 60
- 235000019439 ethyl acetate Nutrition 0.000 description 60
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 57
- 239000000203 mixture Substances 0.000 description 56
- 239000004202 carbamide Substances 0.000 description 54
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 53
- 239000000243 solution Substances 0.000 description 52
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 49
- 238000005481 NMR spectroscopy Methods 0.000 description 48
- 238000006243 chemical reaction Methods 0.000 description 44
- 239000003795 chemical substances by application Substances 0.000 description 43
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 42
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 42
- 239000000377 silicon dioxide Substances 0.000 description 41
- 235000012239 silicon dioxide Nutrition 0.000 description 41
- 239000007787 solid Substances 0.000 description 35
- 239000002253 acid Substances 0.000 description 33
- 238000000746 purification Methods 0.000 description 32
- 238000003756 stirring Methods 0.000 description 29
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 26
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 26
- 229910004298 SiO 2 Inorganic materials 0.000 description 24
- 125000005843 halogen group Chemical group 0.000 description 24
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 21
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 19
- 239000012047 saturated solution Substances 0.000 description 19
- MXUWXRFCWDMFIX-NSCUHMNNSA-N (e)-3-(2-amino-4-chloro-5-methoxyphenyl)prop-2-enoic acid Chemical compound COC1=CC(\C=C\C(O)=O)=C(N)C=C1Cl MXUWXRFCWDMFIX-NSCUHMNNSA-N 0.000 description 17
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 17
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 17
- 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 17
- 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 17
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 17
- 125000004494 ethyl ester group Chemical group 0.000 description 16
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 16
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 15
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 15
- 229910052938 sodium sulfate Inorganic materials 0.000 description 15
- 235000011152 sodium sulphate Nutrition 0.000 description 15
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 14
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
- DSALFNANMWKNOY-NSCUHMNNSA-N (e)-3-(2-acetamido-4-chloro-5-pyrazin-2-ylphenyl)prop-2-enoic acid Chemical compound C1=C(\C=C\C(O)=O)C(NC(=O)C)=CC(Cl)=C1C1=CN=CC=N1 DSALFNANMWKNOY-NSCUHMNNSA-N 0.000 description 13
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 13
- 229910004373 HOAc Inorganic materials 0.000 description 13
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 13
- 239000012346 acetyl chloride Substances 0.000 description 13
- 239000008346 aqueous phase Substances 0.000 description 13
- BAVYZALUXZFZLV-UHFFFAOYSA-N mono-methylamine Natural products NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 13
- QIHACWKSBIJGCC-UHFFFAOYSA-N 7-[(4-fluorophenyl)methyl]-3-oxa-7,9-diazabicyclo[3.3.1]nonane Chemical compound C1=CC(F)=CC=C1CN1CC(N2)COCC2C1 QIHACWKSBIJGCC-UHFFFAOYSA-N 0.000 description 12
- 239000007832 Na2SO4 Substances 0.000 description 12
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 12
- HBHBHJQZCRTBTH-ONEGZZNKSA-N (e)-3-(2-acetamido-4-chloro-5-methoxyphenyl)prop-2-enoic acid Chemical compound COC1=CC(\C=C\C(O)=O)=C(NC(C)=O)C=C1Cl HBHBHJQZCRTBTH-ONEGZZNKSA-N 0.000 description 11
- 238000005859 coupling reaction Methods 0.000 description 11
- 239000012528 membrane Substances 0.000 description 11
- 239000002244 precipitate Substances 0.000 description 11
- 229920006395 saturated elastomer Polymers 0.000 description 11
- 229910000029 sodium carbonate Inorganic materials 0.000 description 11
- FFIFWJWHPXHUSJ-OWOJBTEDSA-N (e)-3-[2-amino-4-chloro-5-(trifluoromethoxy)phenyl]prop-2-enoic acid Chemical compound NC1=CC(Cl)=C(OC(F)(F)F)C=C1\C=C\C(O)=O FFIFWJWHPXHUSJ-OWOJBTEDSA-N 0.000 description 10
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 10
- 208000023275 Autoimmune disease Diseases 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- 238000001953 recrystallisation Methods 0.000 description 10
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 10
- JVAJAWSQEZMCJS-UHFFFAOYSA-N 3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]octane Chemical compound C1=CC(F)=CC=C1CN1CC(N2)CCC2C1 JVAJAWSQEZMCJS-UHFFFAOYSA-N 0.000 description 9
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 9
- 230000008878 coupling Effects 0.000 description 9
- 238000010168 coupling process Methods 0.000 description 9
- 150000004702 methyl esters Chemical class 0.000 description 9
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 9
- 238000010992 reflux Methods 0.000 description 9
- MYDWEKJPDMCIFC-SNAWJCMRSA-N (e)-3-[4-chloro-2-(dimethylsulfamoyl)-5-methoxyphenyl]prop-2-enoic acid Chemical compound COC1=CC(\C=C\C(O)=O)=C(S(=O)(=O)N(C)C)C=C1Cl MYDWEKJPDMCIFC-SNAWJCMRSA-N 0.000 description 8
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 8
- 206010020751 Hypersensitivity Diseases 0.000 description 8
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 8
- 238000001704 evaporation Methods 0.000 description 8
- 230000008020 evaporation Effects 0.000 description 8
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 8
- 229910000027 potassium carbonate Inorganic materials 0.000 description 8
- 150000003254 radicals Chemical class 0.000 description 8
- 235000017550 sodium carbonate Nutrition 0.000 description 8
- IZXWCDITFDNEBY-UHFFFAOYSA-N 1-(chloromethyl)-4-fluorobenzene Chemical compound FC1=CC=C(CCl)C=C1 IZXWCDITFDNEBY-UHFFFAOYSA-N 0.000 description 7
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 7
- 238000001816 cooling Methods 0.000 description 7
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 7
- 230000002757 inflammatory effect Effects 0.000 description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- ZVCDLGYNFYZZOK-UHFFFAOYSA-M sodium cyanate Chemical compound [Na]OC#N ZVCDLGYNFYZZOK-UHFFFAOYSA-M 0.000 description 7
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 7
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 7
- HQUSDQFSOWQSEK-UHFFFAOYSA-N 9-[(4-fluorophenyl)methyl]-3-oxa-7,9-diazabicyclo[3.3.1]nonane Chemical compound C1=CC(F)=CC=C1CN1C2CNCC1COC2 HQUSDQFSOWQSEK-UHFFFAOYSA-N 0.000 description 6
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical group CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 6
- ICPUJELHXWTDFQ-UHFFFAOYSA-N CCCCCC(CC)NC1=CC=C(C=C1)F Chemical compound CCCCCC(CC)NC1=CC=C(C=C1)F ICPUJELHXWTDFQ-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 125000006413 ring segment Chemical group 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- DMUXSGAKEXSNGN-UHFFFAOYSA-N 2-ethyloctanoic acid Chemical compound CCCCCCC(CC)C(O)=O DMUXSGAKEXSNGN-UHFFFAOYSA-N 0.000 description 5
- ONZHMGRKWJMTDE-UHFFFAOYSA-N 3-chloro-4-iodoaniline Chemical compound NC1=CC=C(I)C(Cl)=C1 ONZHMGRKWJMTDE-UHFFFAOYSA-N 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 5
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 5
- 239000007995 HEPES buffer Substances 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 5
- 229910002666 PdCl2 Inorganic materials 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 208000026935 allergic disease Diseases 0.000 description 5
- 229910052786 argon Inorganic materials 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- 230000009610 hypersensitivity Effects 0.000 description 5
- ZCYXXKJEDCHMGH-UHFFFAOYSA-N nonane Chemical compound CCCC[CH]CCCC ZCYXXKJEDCHMGH-UHFFFAOYSA-N 0.000 description 5
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 5
- 238000004007 reversed phase HPLC Methods 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 5
- HBJXYAKSFBJTSF-AATRIKPKSA-N (e)-3-(2-acetamido-4-chloro-5-pyridin-2-ylphenyl)prop-2-enoic acid Chemical compound C1=C(\C=C\C(O)=O)C(NC(=O)C)=CC(Cl)=C1C1=CC=CC=N1 HBJXYAKSFBJTSF-AATRIKPKSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 4
- 208000029523 Interstitial Lung disease Diseases 0.000 description 4
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 239000012452 mother liquor Substances 0.000 description 4
- HGDAFIJKXCFHPG-UHFFFAOYSA-N n-(5-chloro-2-hydroxyphenyl)acetamide Chemical compound CC(=O)NC1=CC(Cl)=CC=C1O HGDAFIJKXCFHPG-UHFFFAOYSA-N 0.000 description 4
- BKIMMITUMNQMOS-UHFFFAOYSA-N normal nonane Natural products CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 4
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 4
- 235000015320 potassium carbonate Nutrition 0.000 description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- GYUURHMITDQTRU-UHFFFAOYSA-N tributyl(pyridin-2-yl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C1=CC=CC=N1 GYUURHMITDQTRU-UHFFFAOYSA-N 0.000 description 4
- 239000008096 xylene Substances 0.000 description 4
- HAHMFVSMJULLJX-NSCUHMNNSA-N (e)-3-(2-acetamido-4-chloro-5-fluorophenyl)prop-2-enoic acid Chemical compound CC(=O)NC1=CC(Cl)=C(F)C=C1\C=C\C(O)=O HAHMFVSMJULLJX-NSCUHMNNSA-N 0.000 description 3
- QVXDFXBLXLLMEX-ONEGZZNKSA-N (e)-3-[2-amino-4-chloro-5-(cyclopropylmethoxy)phenyl]prop-2-enoic acid Chemical compound C1=C(\C=C\C(O)=O)C(N)=CC(Cl)=C1OCC1CC1 QVXDFXBLXLLMEX-ONEGZZNKSA-N 0.000 description 3
- OOXDZWWHAPWHLG-FNORWQNLSA-N (e)-3-[4-chloro-2-[(2-methylpropan-2-yl)oxycarbonylamino]phenyl]prop-2-enoic acid Chemical compound CC(C)(C)OC(=O)NC1=CC(Cl)=CC=C1\C=C\C(O)=O OOXDZWWHAPWHLG-FNORWQNLSA-N 0.000 description 3
- OYKPVXIOTZMOKW-UHFFFAOYSA-N 2-bromo-5-chloro-4-methoxyaniline Chemical compound COC1=CC(Br)=C(N)C=C1Cl OYKPVXIOTZMOKW-UHFFFAOYSA-N 0.000 description 3
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 3
- XSYMMAWAJUCOOJ-UHFFFAOYSA-N 7-benzyl-9-[(4-fluorophenyl)methyl]-3-oxa-7,9-diazabicyclo[3.3.1]nonane Chemical compound C1=CC(F)=CC=C1CN1C2COCC1CN(CC=1C=CC=CC=1)C2 XSYMMAWAJUCOOJ-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 206010065687 Bone loss Diseases 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- 208000031481 Pathologic Constriction Diseases 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 229960003444 immunosuppressant agent Drugs 0.000 description 3
- 230000001861 immunosuppressant effect Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 230000009826 neoplastic cell growth Effects 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 208000037803 restenosis Diseases 0.000 description 3
- 230000036262 stenosis Effects 0.000 description 3
- 208000037804 stenosis Diseases 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 3
- IIFVWLUQBAIPMJ-UHFFFAOYSA-N (4-fluorophenyl)methanamine Chemical compound NCC1=CC=C(F)C=C1 IIFVWLUQBAIPMJ-UHFFFAOYSA-N 0.000 description 2
- HEYBQMZOLPGLSU-ONEGZZNKSA-N (e)-3-(2-acetamido-4-chloro-5-methylphenyl)prop-2-enoic acid Chemical compound CC(=O)NC1=CC(Cl)=C(C)C=C1\C=C\C(O)=O HEYBQMZOLPGLSU-ONEGZZNKSA-N 0.000 description 2
- ZSXMMUKIEIOLTL-NSCUHMNNSA-N (e)-3-(2-amino-4-chloro-5-methylphenyl)prop-2-enoic acid Chemical compound CC1=CC(\C=C\C(O)=O)=C(N)C=C1Cl ZSXMMUKIEIOLTL-NSCUHMNNSA-N 0.000 description 2
- ADAONTJPMJJDBL-ONEGZZNKSA-N (e)-3-[4-chloro-2-(dimethylsulfamoyl)-5-(trifluoromethoxy)phenyl]prop-2-enoic acid Chemical compound CN(C)S(=O)(=O)C1=CC(Cl)=C(OC(F)(F)F)C=C1\C=C\C(O)=O ADAONTJPMJJDBL-ONEGZZNKSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- NKQOLGXECGOTQU-UHFFFAOYSA-N 1-bromo-4-chloro-5-(cyclopropylmethoxy)-2-nitrobenzene Chemical compound C1=C(Br)C([N+](=O)[O-])=CC(Cl)=C1OCC1CC1 NKQOLGXECGOTQU-UHFFFAOYSA-N 0.000 description 2
- WKJOQYHMXRVQDK-UHFFFAOYSA-N 2-(dimethylamino)acetamide Chemical compound CN(C)CC(N)=O WKJOQYHMXRVQDK-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- GHOZODHBVXYTEO-UHFFFAOYSA-N 2-bromo-5-chloro-4-methoxybenzenesulfonyl chloride Chemical compound COC1=CC(Br)=C(S(Cl)(=O)=O)C=C1Cl GHOZODHBVXYTEO-UHFFFAOYSA-N 0.000 description 2
- JJKWHOSQTYYFAE-UHFFFAOYSA-N 2-methoxyacetyl chloride Chemical compound COCC(Cl)=O JJKWHOSQTYYFAE-UHFFFAOYSA-N 0.000 description 2
- SNGGAGSGIFAHDI-UHFFFAOYSA-N 3,9-dibenzyl-3,7,9-triazabicyclo[3.3.1]nonane Chemical compound C=1C=CC=CC=1CN(C1)CC2CNCC1N2CC1=CC=CC=C1 SNGGAGSGIFAHDI-UHFFFAOYSA-N 0.000 description 2
- UAMVKOTWSHJOSY-UHFFFAOYSA-N 4-bromo-1-chloro-2-methoxybenzene Chemical compound COC1=CC(Br)=CC=C1Cl UAMVKOTWSHJOSY-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- 125000004863 4-trifluoromethoxyphenyl group Chemical group [H]C1=C([H])C(OC(F)(F)F)=C([H])C([H])=C1* 0.000 description 2
- WGVPKSGCOCWNFG-UHFFFAOYSA-N 5-bromo-2-chloro-4-nitrophenol Chemical compound OC1=CC(Br)=C([N+]([O-])=O)C=C1Cl WGVPKSGCOCWNFG-UHFFFAOYSA-N 0.000 description 2
- UEVFFMZHGNYDKM-UHFFFAOYSA-N 5-bromo-2-chlorophenol Chemical compound OC1=CC(Br)=CC=C1Cl UEVFFMZHGNYDKM-UHFFFAOYSA-N 0.000 description 2
- DNJISDOOOWGSFN-UHFFFAOYSA-N 9-benzyl-3-oxa-7,9-diazabicyclo[3.3.1]nonane Chemical compound C1OCC2CNCC1N2CC1=CC=CC=C1 DNJISDOOOWGSFN-UHFFFAOYSA-N 0.000 description 2
- 206010027654 Allergic conditions Diseases 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 2
- 108010008165 Etanercept Proteins 0.000 description 2
- OUVXYXNWSVIOSJ-UHFFFAOYSA-N Fluo-4 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)N(CC(O)=O)CC(O)=O)=C1 OUVXYXNWSVIOSJ-UHFFFAOYSA-N 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- 101000777564 Homo sapiens C-C chemokine receptor type 1 Proteins 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical group CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- IDRGFNPZDVBSSE-UHFFFAOYSA-N OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F Chemical compound OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F IDRGFNPZDVBSSE-UHFFFAOYSA-N 0.000 description 2
- 208000022873 Ocular disease Diseases 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- 238000006619 Stille reaction Methods 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- VYWQTJWGWLKBQA-UHFFFAOYSA-N [amino(hydroxy)methylidene]azanium;chloride Chemical compound Cl.NC(N)=O VYWQTJWGWLKBQA-UHFFFAOYSA-N 0.000 description 2
- RSWGJHLUYNHPMX-ONCXSQPRSA-N abietic acid Chemical compound C([C@@H]12)CC(C(C)C)=CC1=CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C(O)=O RSWGJHLUYNHPMX-ONCXSQPRSA-N 0.000 description 2
- 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 201000001981 dermatomyositis Diseases 0.000 description 2
- 239000012954 diazonium Substances 0.000 description 2
- 150000001989 diazonium salts Chemical class 0.000 description 2
- QKIUAMUSENSFQQ-UHFFFAOYSA-N dimethylazanide Chemical compound C[N-]C QKIUAMUSENSFQQ-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- LOJCCIVIYKJRFE-UHFFFAOYSA-N ethyl 2-(2-amino-4-chloro-5-methylphenyl)prop-2-enoate Chemical compound CCOC(=O)C(=C)C1=CC(C)=C(Cl)C=C1N LOJCCIVIYKJRFE-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 238000000990 heteronuclear single quantum coherence spectrum Methods 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 102000043450 human CCR1 Human genes 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 2
- 230000020477 pH reduction Effects 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 201000000306 sarcoidosis Diseases 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 150000008054 sulfonate salts Chemical class 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- CFQJBWKKHCMCGJ-UHFFFAOYSA-N tributyl(pyridin-3-yl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C1=CC=CN=C1 CFQJBWKKHCMCGJ-UHFFFAOYSA-N 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- COIOYMYWGDAQPM-UHFFFAOYSA-N tris(2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C COIOYMYWGDAQPM-UHFFFAOYSA-N 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- QBMHZZHJIBUPOX-UHFFFAOYSA-N (3-aminophenyl)boronic acid;hydron;chloride Chemical compound Cl.NC1=CC=CC(B(O)O)=C1 QBMHZZHJIBUPOX-UHFFFAOYSA-N 0.000 description 1
- MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 1
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
- VNLODBPNDFBDLV-DUXPYHPUSA-N (E)-5-[1-chloro-9-[(4-fluorophenyl)methyl]-7-methyl-3,7,9-triazabicyclo[3.3.1]nonan-3-yl]-5-oxopent-3-enamide Chemical compound C1N(C)CC2CN(C(=O)\C=C\CC(N)=O)CC1(Cl)N2CC1=CC=C(F)C=C1 VNLODBPNDFBDLV-DUXPYHPUSA-N 0.000 description 1
- WSJAVQUMQBZLIX-SNAWJCMRSA-N (e)-3-(2-acetamido-4-chloro-3,5-dimethoxyphenyl)prop-2-enoic acid Chemical compound COC1=CC(\C=C\C(O)=O)=C(NC(C)=O)C(OC)=C1Cl WSJAVQUMQBZLIX-SNAWJCMRSA-N 0.000 description 1
- KSHXLDJIFQQKBK-GQCTYLIASA-N (e)-3-(2-acetamido-4-chloro-3-methoxyphenyl)prop-2-enoic acid Chemical compound COC1=C(Cl)C=CC(\C=C\C(O)=O)=C1NC(C)=O KSHXLDJIFQQKBK-GQCTYLIASA-N 0.000 description 1
- QQFOIQWDSJTIIS-SNAWJCMRSA-N (e)-3-(2-acetamido-4-chloro-5-pyridin-3-ylphenyl)prop-2-enoic acid Chemical compound C1=C(\C=C\C(O)=O)C(NC(=O)C)=CC(Cl)=C1C1=CC=CN=C1 QQFOIQWDSJTIIS-SNAWJCMRSA-N 0.000 description 1
- PLETVPNOXSXQSR-ONEGZZNKSA-N (e)-3-(4-chloro-5-ethoxy-2-nitrophenyl)prop-2-enoic acid Chemical compound CCOC1=CC(\C=C\C(O)=O)=C([N+]([O-])=O)C=C1Cl PLETVPNOXSXQSR-ONEGZZNKSA-N 0.000 description 1
- MEQVKZOCDAGQKM-OWOJBTEDSA-N (e)-3-(5-bromo-4-chloro-2-nitrophenyl)prop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CC(Br)=C(Cl)C=C1[N+]([O-])=O MEQVKZOCDAGQKM-OWOJBTEDSA-N 0.000 description 1
- VEYTYRQRTPRMHJ-NSCUHMNNSA-N (e)-3-[2-acetamido-4-chloro-5-(trifluoromethoxy)phenyl]prop-2-enoic acid Chemical compound CC(=O)NC1=CC(Cl)=C(OC(F)(F)F)C=C1\C=C\C(O)=O VEYTYRQRTPRMHJ-NSCUHMNNSA-N 0.000 description 1
- OXOXBOQPACHBJJ-SNAWJCMRSA-N (e)-3-[4-chloro-2-(dimethylsulfamoyl)-5-methylphenyl]prop-2-enoic acid Chemical compound CN(C)S(=O)(=O)C1=CC(Cl)=C(C)C=C1\C=C\C(O)=O OXOXBOQPACHBJJ-SNAWJCMRSA-N 0.000 description 1
- ZECIYOYICFNUCZ-DUXPYHPUSA-N (e)-3-[4-chloro-2-[(2,2,2-trifluoroacetyl)amino]phenyl]prop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CC=C(Cl)C=C1NC(=O)C(F)(F)F ZECIYOYICFNUCZ-DUXPYHPUSA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 1
- APWRZPQBPCAXFP-UHFFFAOYSA-N 1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide Chemical compound O=C1NC=CC2=C(C=CC=C12)N1N=CC(=C1C(F)(F)F)C(=O)NC1=CC(=NC=C1)C(F)(F)F APWRZPQBPCAXFP-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- CBPQYCHYMFLLNO-RUDMXATFSA-N 1-[5-chloro-2-[(e)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]octan-8-yl]-3-oxoprop-1-enyl]-4-(trifluoromethoxy)phenyl]-3-methylurea Chemical compound CNC(=O)NC1=CC(Cl)=C(OC(F)(F)F)C=C1\C=C\C(=O)N1C2CCC1CN(CC=1C=CC(F)=CC=1)C2 CBPQYCHYMFLLNO-RUDMXATFSA-N 0.000 description 1
- OEWRLZBZEGABJE-BJMVGYQFSA-N 1-[5-chloro-2-[(e)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]octan-8-yl]-3-oxoprop-1-enyl]-4-methoxyphenyl]-3-methylurea Chemical compound CNC(=O)NC1=CC(Cl)=C(OC)C=C1\C=C\C(=O)N1C2CCC1CN(CC=1C=CC(F)=CC=1)C2 OEWRLZBZEGABJE-BJMVGYQFSA-N 0.000 description 1
- BMKRVNUKPVZLPR-BJMVGYQFSA-N 1-[5-chloro-2-[(e)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]octan-8-yl]-3-oxoprop-1-enyl]-4-methylphenyl]-3-methylurea Chemical compound CNC(=O)NC1=CC(Cl)=C(C)C=C1\C=C\C(=O)N1C2CCC1CN(CC=1C=CC(F)=CC=1)C2 BMKRVNUKPVZLPR-BJMVGYQFSA-N 0.000 description 1
- CFNOLVOGGAQVSV-RUDMXATFSA-N 1-[5-chloro-2-[(e)-3-[7-[(4-fluorophenyl)methyl]-3-oxa-7,9-diazabicyclo[3.3.1]nonan-9-yl]-3-oxoprop-1-enyl]-4-methoxyphenyl]-3-cyclopropylurea Chemical compound C1CC1NC(=O)NC=1C=C(Cl)C(OC)=CC=1\C=C\C(=O)N1C(C2)COCC1CN2CC1=CC=C(F)C=C1 CFNOLVOGGAQVSV-RUDMXATFSA-N 0.000 description 1
- VGEAVTCRYVDVGT-VMPITWQZSA-N 1-[5-chloro-2-[(e)-3-[7-[(4-fluorophenyl)methyl]-3-oxa-7,9-diazabicyclo[3.3.1]nonan-9-yl]-3-oxoprop-1-enyl]-4-methoxyphenyl]-3-methylurea Chemical compound CNC(=O)NC1=CC(Cl)=C(OC)C=C1\C=C\C(=O)N1C2COCC1CN(CC=1C=CC(F)=CC=1)C2 VGEAVTCRYVDVGT-VMPITWQZSA-N 0.000 description 1
- PAJPWUMXBYXFCZ-UHFFFAOYSA-N 1-aminocyclopropanecarboxylic acid Chemical compound OC(=O)C1(N)CC1 PAJPWUMXBYXFCZ-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- NSWDFZVKCGMQNK-KPKJPENVSA-N 1-tert-butylsulfonyl-1-[5-chloro-2-[(e)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]octan-8-yl]-3-oxoprop-1-enyl]-4-methylphenyl]urea Chemical compound C1=C(Cl)C(C)=CC(\C=C\C(=O)N2C3CCC2CN(CC=2C=CC(F)=CC=2)C3)=C1N(C(N)=O)S(=O)(=O)C(C)(C)C NSWDFZVKCGMQNK-KPKJPENVSA-N 0.000 description 1
- WUZXWBJAZVSTRD-UHFFFAOYSA-N 2-(2-amino-4-chloro-5-methylphenyl)prop-2-enoic acid Chemical compound CC1=CC(C(=C)C(O)=O)=C(N)C=C1Cl WUZXWBJAZVSTRD-UHFFFAOYSA-N 0.000 description 1
- VWACKXUUYAGZNR-UHFFFAOYSA-N 2-(4-amino-5-bromo-2-chlorophenyl)propan-2-ol Chemical compound CC(C)(O)C1=CC(Br)=C(N)C=C1Cl VWACKXUUYAGZNR-UHFFFAOYSA-N 0.000 description 1
- JQGCTAAHBMFDJB-UHFFFAOYSA-N 2-[5-chloro-2-[3-[3-[(4-fluorophenyl)methyl]-3,9-diazabicyclo[3.3.1]nonan-9-yl]-3-oxoprop-1-enyl]phenyl]-1-cyanoguanidine Chemical compound C1=CC(F)=CC=C1CN1CC(N2C(=O)C=CC=3C(=CC(Cl)=CC=3)NC(=N)NC#N)CCCC2C1 JQGCTAAHBMFDJB-UHFFFAOYSA-N 0.000 description 1
- SGCDQDCWNCQXQH-UHFFFAOYSA-N 2-[[tert-butyl(dimethyl)silyl]oxymethyl]-3-[3-[2-[tert-butyl(dimethyl)silyl]oxy-6-methylphenyl]sulfonyloxypropoxy]-1-phenylpropane-1-sulfonic acid Chemical compound CC1=C(C(=CC=C1)O[Si](C)(C)C(C)(C)C)S(=O)(=O)OCCCOCC(CO[Si](C)(C)C(C)(C)C)C(C2=CC=CC=C2)S(=O)(=O)O SGCDQDCWNCQXQH-UHFFFAOYSA-N 0.000 description 1
- XLRJBJOEZXTODG-UHFFFAOYSA-N 2-bromo-5-chloro-4-(cyclopropylmethoxy)aniline Chemical compound C1=C(Br)C(N)=CC(Cl)=C1OCC1CC1 XLRJBJOEZXTODG-UHFFFAOYSA-N 0.000 description 1
- QNKQNJJCNWUOHC-UHFFFAOYSA-N 2-bromo-5-chloro-4-fluoroaniline Chemical compound NC1=CC(Cl)=C(F)C=C1Br QNKQNJJCNWUOHC-UHFFFAOYSA-N 0.000 description 1
- ULCBEYQOSOVMMA-UHFFFAOYSA-N 2-bromo-5-chloro-4-methylaniline Chemical compound CC1=CC(Br)=C(N)C=C1Cl ULCBEYQOSOVMMA-UHFFFAOYSA-N 0.000 description 1
- LDCDTGUIDNWXCT-UHFFFAOYSA-N 2-bromo-5-chloro-4-pyrazin-2-ylaniline Chemical compound C1=C(Br)C(N)=CC(Cl)=C1C1=CN=CC=N1 LDCDTGUIDNWXCT-UHFFFAOYSA-N 0.000 description 1
- BWCHBIRAZUICGC-UHFFFAOYSA-N 2-chloro-1-[9-[(4-fluorophenyl)methyl]-3-oxa-7,9-diazabicyclo[3.3.1]nonan-7-yl]ethanone Chemical compound C1=CC(F)=CC=C1CN1C2COCC1CN(C(=O)CCl)C2 BWCHBIRAZUICGC-UHFFFAOYSA-N 0.000 description 1
- SZIFAVKTNFCBPC-UHFFFAOYSA-N 2-chloroethanol Chemical compound OCCCl SZIFAVKTNFCBPC-UHFFFAOYSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- LBYVZRFDLNAPRC-UHFFFAOYSA-N 2-sulfanylguanidine Chemical class NC(=N)NS LBYVZRFDLNAPRC-UHFFFAOYSA-N 0.000 description 1
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
- UTMCNQPKBBHRPR-UHFFFAOYSA-N 3,7,9-triazabicyclo[3.3.1]nonane-3-carboxylic acid Chemical compound C12CN(CC(CNC1)N2)C(=O)O UTMCNQPKBBHRPR-UHFFFAOYSA-N 0.000 description 1
- QQZDECZROKFYDQ-UHFFFAOYSA-N 3,8-diazabicyclo[3.2.1]octane;dihydrochloride Chemical compound Cl.Cl.C1NCC2CCC1N2 QQZDECZROKFYDQ-UHFFFAOYSA-N 0.000 description 1
- SBNWFFCJMRMXMX-UHFFFAOYSA-N 3,9-dibenzyl-7-methyl-3,7,9-triazabicyclo[3.3.1]nonane Chemical compound C1C(N2CC=3C=CC=CC=3)CN(C)CC2CN1CC1=CC=CC=C1 SBNWFFCJMRMXMX-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- MXUWXRFCWDMFIX-UHFFFAOYSA-N 3-(2-amino-4-chloro-5-methoxyphenyl)prop-2-enoic acid Chemical compound COC1=CC(C=CC(O)=O)=C(N)C=C1Cl MXUWXRFCWDMFIX-UHFFFAOYSA-N 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- WATARWUBGJZHEH-UHFFFAOYSA-N 3-(benzenesulfonyl)-7,9-dibenzyl-3,7,9-triazabicyclo[3.2.2]nonane Chemical compound C=1C=CC=CC=1S(=O)(=O)N(CC1CN2CC=3C=CC=CC=3)CC2CN1CC1=CC=CC=C1 WATARWUBGJZHEH-UHFFFAOYSA-N 0.000 description 1
- KMXLOXBKKBAMKU-UHFFFAOYSA-N 3-(benzenesulfonyl)-7,9-dibenzyl-3,7,9-triazabicyclo[3.3.1]nonane Chemical compound C=1C=CC=CC=1S(=O)(=O)N(CC(C1)N2CC=3C=CC=CC=3)CC2CN1CC1=CC=CC=C1 KMXLOXBKKBAMKU-UHFFFAOYSA-N 0.000 description 1
- UREHVSYFEXKYIO-UHFFFAOYSA-N 3-[(4-fluorophenyl)methyl]-3,9-diazabicyclo[3.3.1]nonane Chemical compound C1=CC(F)=CC=C1CN1CC(N2)CCCC2C1 UREHVSYFEXKYIO-UHFFFAOYSA-N 0.000 description 1
- MUUXKBIBWGTKRX-UHFFFAOYSA-N 3-[(4-fluorophenyl)methyl]-7-methyl-3,7,9-triazabicyclo[3.3.1]nonane Chemical compound C1C(N2)CN(C)CC2CN1CC1=CC=C(F)C=C1 MUUXKBIBWGTKRX-UHFFFAOYSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- ACBHEGPKUJLJQG-BJMVGYQFSA-N 3-[5-chloro-2-[(e)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]octan-8-yl]-3-oxoprop-1-enyl]-4-(trifluoromethoxy)phenyl]-1,1-dimethylurea Chemical compound CN(C)C(=O)NC1=CC(Cl)=C(OC(F)(F)F)C=C1\C=C\C(=O)N1C2CCC1CN(CC=1C=CC(F)=CC=1)C2 ACBHEGPKUJLJQG-BJMVGYQFSA-N 0.000 description 1
- WXYUMBFYYOWTDI-IZZDOVSWSA-N 3-[5-chloro-2-[(e)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]octan-8-yl]-3-oxoprop-1-enyl]-4-methoxyphenyl]-1,1-dimethylurea Chemical compound C1=C(Cl)C(OC)=CC(\C=C\C(=O)N2C3CCC2CN(CC=2C=CC(F)=CC=2)C3)=C1NC(=O)N(C)C WXYUMBFYYOWTDI-IZZDOVSWSA-N 0.000 description 1
- GPNIJIJFLZKGAQ-BJMVGYQFSA-N 3-[5-chloro-2-[(e)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]octan-8-yl]-3-oxoprop-1-enyl]-4-methoxyphenyl]-5-methylimidazolidine-2,4-dione Chemical compound O=C1NC(C)C(=O)N1C=1C=C(Cl)C(OC)=CC=1\C=C\C(=O)N1C(C2)CCC1CN2CC1=CC=C(F)C=C1 GPNIJIJFLZKGAQ-BJMVGYQFSA-N 0.000 description 1
- BEZGHDRLDURVRK-UHFFFAOYSA-N 3-chloro-2,4-dimethoxyaniline Chemical compound COC1=CC=C(N)C(OC)=C1Cl BEZGHDRLDURVRK-UHFFFAOYSA-N 0.000 description 1
- VPZJHTWLWKFPQW-UHFFFAOYSA-N 3-chloro-2-methoxyaniline Chemical compound COC1=C(N)C=CC=C1Cl VPZJHTWLWKFPQW-UHFFFAOYSA-N 0.000 description 1
- ZPKUUNGPBSRPRM-UHFFFAOYSA-N 3-chloro-4-(trifluoromethoxy)aniline Chemical compound NC1=CC=C(OC(F)(F)F)C(Cl)=C1 ZPKUUNGPBSRPRM-UHFFFAOYSA-N 0.000 description 1
- XQVCBOLNTSUFGD-UHFFFAOYSA-N 3-chloro-4-methoxyaniline Chemical compound COC1=CC=C(N)C=C1Cl XQVCBOLNTSUFGD-UHFFFAOYSA-N 0.000 description 1
- RQKFYFNZSHWXAW-UHFFFAOYSA-N 3-chloro-p-toluidine Chemical compound CC1=CC=C(N)C=C1Cl RQKFYFNZSHWXAW-UHFFFAOYSA-N 0.000 description 1
- LCJYCXCKWIGABR-UHFFFAOYSA-N 3-methyl-3,7,9-triazabicyclo[3.3.1]nonane;dihydrochloride Chemical compound Cl.Cl.C1NCC2CN(C)CC1N2 LCJYCXCKWIGABR-UHFFFAOYSA-N 0.000 description 1
- RWTBDPVVFMCIEQ-UHFFFAOYSA-N 3-oxa-7,9-diazabicyclo[3.3.1]nonane-7,9-dicarboxylic acid Chemical compound C12COCC(CN(C1)C(=O)O)N2C(=O)O RWTBDPVVFMCIEQ-UHFFFAOYSA-N 0.000 description 1
- SEGJKQMREQTCPX-UHFFFAOYSA-N 3-oxa-7,9-diazabicyclo[3.3.1]nonane-7-carboxylic acid Chemical compound C1OCC2CN(C(=O)O)CC1N2 SEGJKQMREQTCPX-UHFFFAOYSA-N 0.000 description 1
- ABZGTIUIMHXVIS-UHFFFAOYSA-N 3-oxopiperazine-1-carboxylic acid Chemical compound OC(=O)N1CCNC(=O)C1 ABZGTIUIMHXVIS-UHFFFAOYSA-N 0.000 description 1
- ALDOZKXIKPFFOY-UHFFFAOYSA-N 4-[(4-fluorophenyl)methyl]morpholine Chemical compound C1=CC(F)=CC=C1CN1CCOCC1 ALDOZKXIKPFFOY-UHFFFAOYSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- DDSOBJRYRNZXHV-UHFFFAOYSA-N 4-fluoro-N-octylaniline Chemical compound CCCCCCCCNC1=CC=C(F)C=C1 DDSOBJRYRNZXHV-UHFFFAOYSA-N 0.000 description 1
- KRZCOLNOCZKSDF-UHFFFAOYSA-N 4-fluoroaniline Chemical compound NC1=CC=C(F)C=C1 KRZCOLNOCZKSDF-UHFFFAOYSA-N 0.000 description 1
- IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 1
- JYXKLHDTWONABR-UHFFFAOYSA-N 5-bromo-4-chloro-2-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC(Cl)=C(Br)C=C1C=O JYXKLHDTWONABR-UHFFFAOYSA-N 0.000 description 1
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
- WLHALLKXPAGJAL-FPYGCLRLSA-N 6-[5-chloro-2-[(e)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]octan-8-yl]-3-oxoprop-1-enyl]-4-(trifluoromethoxy)phenyl]-4,6-diazaspiro[2.4]heptane-5,7-dione Chemical compound C1=CC(F)=CC=C1CN1CC(N2C(=O)\C=C\C=3C(=CC(Cl)=C(OC(F)(F)F)C=3)N3C(C4(CC4)NC3=O)=O)CCC2C1 WLHALLKXPAGJAL-FPYGCLRLSA-N 0.000 description 1
- BSFXEVNXFGPXCL-RUDMXATFSA-N 6-[5-chloro-2-[(e)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]octan-8-yl]-3-oxoprop-1-enyl]-4-methoxyphenyl]-4,6-diazaspiro[2.4]heptane-5,7-dione Chemical compound O=C1NC2(CC2)C(=O)N1C=1C=C(Cl)C(OC)=CC=1\C=C\C(=O)N1C(C2)CCC1CN2CC1=CC=C(F)C=C1 BSFXEVNXFGPXCL-RUDMXATFSA-N 0.000 description 1
- JSWHDHBXIHEXAL-FPYGCLRLSA-N 6-[5-chloro-4-fluoro-2-[(e)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]octan-8-yl]-3-oxoprop-1-enyl]phenyl]-4,6-diazaspiro[2.4]heptane-5,7-dione Chemical compound C1=CC(F)=CC=C1CN1CC(N2C(=O)\C=C\C=3C(=CC(Cl)=C(F)C=3)N3C(C4(CC4)NC3=O)=O)CCC2C1 JSWHDHBXIHEXAL-FPYGCLRLSA-N 0.000 description 1
- KTJKRZAOQUYRHF-UHFFFAOYSA-N 7-(2-chloroacetyl)-3,7,9-triazabicyclo[3.3.1]nonane-3-carboxylic acid Chemical compound ClCC(=O)N1CC2CN(CC(C1)N2)C(=O)O KTJKRZAOQUYRHF-UHFFFAOYSA-N 0.000 description 1
- OHVTZXPIBYHIDV-UHFFFAOYSA-N 7-(benzenesulfonyl)-9-benzyl-3-oxa-7,9-diazabicyclo[3.3.1]nonane Chemical compound C=1C=CC=CC=1S(=O)(=O)N(C1)CC2COCC1N2CC1=CC=CC=C1 OHVTZXPIBYHIDV-UHFFFAOYSA-N 0.000 description 1
- IMARPSHXZIKABT-UHFFFAOYSA-N 7-[(4-fluorophenyl)methyl]-3,7,9-triazabicyclo[3.3.1]nonane-3-carboxylic acid Chemical compound FC1=CC=C(CN2CC3CN(CC(C2)N3)C(=O)O)C=C1 IMARPSHXZIKABT-UHFFFAOYSA-N 0.000 description 1
- KQNOLQZUQNLPLU-UHFFFAOYSA-N 7-[2-(2-acetamido-4-chlorophenoxy)acetyl]-3,7,9-triazabicyclo[3.3.1]nonane-3-carboxylic acid Chemical compound C(C)(=O)NC1=C(OCC(=O)N2CC3CN(CC(C2)N3)C(=O)O)C=CC(=C1)Cl KQNOLQZUQNLPLU-UHFFFAOYSA-N 0.000 description 1
- SLLWALHBEBMXSC-UHFFFAOYSA-N 7-benzyl-3-oxa-7-azabicyclo[3.3.1]nonan-9-one Chemical compound O=C1C(C2)COCC1CN2CC1=CC=CC=C1 SLLWALHBEBMXSC-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- XCUYMNUWMYBVFX-UHFFFAOYSA-N 9-[(4-fluorophenyl)methyl]-7-methyl-3,7,9-triazabicyclo[3.3.1]nonane-3-carboxylic acid Chemical compound FC1=CC=C(CN2C3CN(CC2CN(C3)C)C(=O)O)C=C1 XCUYMNUWMYBVFX-UHFFFAOYSA-N 0.000 description 1
- QNGMGMDGAYWQHD-UHFFFAOYSA-N 9-benzyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-one Chemical compound C1C(=O)CC2COCC1N2CC1=CC=CC=C1 QNGMGMDGAYWQHD-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- NREJKQGRYUDLIV-UHFFFAOYSA-N CN1CC2CN(CC(C1)N2)C(=O)O Chemical compound CN1CC2CN(CC(C1)N2)C(=O)O NREJKQGRYUDLIV-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 235000014036 Castanea Nutrition 0.000 description 1
- 241001070941 Castanea Species 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- YIIMEMSDCNDGTB-UHFFFAOYSA-N Dimethylcarbamoyl chloride Chemical compound CN(C)C(Cl)=O YIIMEMSDCNDGTB-UHFFFAOYSA-N 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 206010060742 Endocrine ophthalmopathy Diseases 0.000 description 1
- 206010014824 Endotoxic shock Diseases 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 206010019755 Hepatitis chronic active Diseases 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 208000004883 Lipoid Nephrosis Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- VQJKABVONAKFJA-UHFFFAOYSA-N N-methylidene-4-(trifluoromethoxy)benzenesulfonamide Chemical compound FC(F)(F)Oc1ccc(cc1)S(=O)(=O)N=C VQJKABVONAKFJA-UHFFFAOYSA-N 0.000 description 1
- 208000034827 Neointima Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 206010065159 Polychondritis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000006045 Spondylarthropathies Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical group O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 208000016807 X-linked intellectual disability-macrocephaly-macroorchidism syndrome Diseases 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- XTORCRXTQAEYSA-FPYGCLRLSA-N [5-chloro-2-[(e)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]octan-8-yl]-3-oxoprop-1-enyl]-4-(trifluoromethoxy)phenyl]urea Chemical compound NC(=O)NC1=CC(Cl)=C(OC(F)(F)F)C=C1\C=C\C(=O)N1C2CCC1CN(CC=1C=CC(F)=CC=1)C2 XTORCRXTQAEYSA-FPYGCLRLSA-N 0.000 description 1
- UZHFLDHBRPTPST-RUDMXATFSA-N [5-chloro-2-[(e)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]octan-8-yl]-3-oxoprop-1-enyl]-4-methylphenyl]urea Chemical compound C1=C(Cl)C(C)=CC(\C=C\C(=O)N2C3CCC2CN(CC=2C=CC(F)=CC=2)C3)=C1NC(N)=O UZHFLDHBRPTPST-RUDMXATFSA-N 0.000 description 1
- CCGILYGVXQDZEW-WEVVVXLNSA-N [5-chloro-2-[(e)-3-[3-[(4-fluorophenyl)methyl]-7-methyl-3,7,9-triazabicyclo[3.3.1]nonan-9-yl]-3-oxoprop-1-enyl]phenyl]urea Chemical compound C1C(N2C(=O)\C=C\C=3C(=CC(Cl)=CC=3)NC(N)=O)CN(C)CC2CN1CC1=CC=C(F)C=C1 CCGILYGVXQDZEW-WEVVVXLNSA-N 0.000 description 1
- ICYHXAZDGFXPBV-XBXARRHUSA-N [5-chloro-2-[(e)-3-[7-[(4-fluorophenyl)methyl]-3-oxa-7,9-diazabicyclo[3.3.1]nonan-9-yl]-3-oxoprop-1-enyl]phenyl]urea Chemical compound NC(=O)NC1=CC(Cl)=CC=C1\C=C\C(=O)N1C2COCC1CN(CC=1C=CC(F)=CC=1)C2 ICYHXAZDGFXPBV-XBXARRHUSA-N 0.000 description 1
- KXGMWAIMWUIYOE-QPJJXVBHSA-N [5-chloro-2-[(e)-3-[9-[(4-fluorophenyl)methyl]-3-oxa-7,9-diazabicyclo[3.3.1]nonan-7-yl]-3-oxoprop-1-enyl]-4-methoxyphenyl]urea Chemical compound C1=C(Cl)C(OC)=CC(\C=C\C(=O)N2CC3COCC(N3CC=3C=CC(F)=CC=3)C2)=C1NC(N)=O KXGMWAIMWUIYOE-QPJJXVBHSA-N 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- AXJDEHNQPMZKOS-UHFFFAOYSA-N acetylazanium;chloride Chemical compound [Cl-].CC([NH3+])=O AXJDEHNQPMZKOS-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 208000002029 allergic contact dermatitis Diseases 0.000 description 1
- 208000028004 allergic respiratory disease Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229960004238 anakinra Drugs 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004600 benzothiopyranyl group Chemical group S1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Chemical group 0.000 description 1
- AEILLAXRDHDKDY-UHFFFAOYSA-N bromomethylcyclopropane Chemical compound BrCC1CC1 AEILLAXRDHDKDY-UHFFFAOYSA-N 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 230000001275 ca(2+)-mobilization Effects 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000008414 cartilage metabolism Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 1
- WRJWRGBVPUUDLA-UHFFFAOYSA-N chlorosulfonyl isocyanate Chemical compound ClS(=O)(=O)N=C=O WRJWRGBVPUUDLA-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 239000000498 cooling water Substances 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000005100 correlation spectroscopy Methods 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- ZOOSILUVXHVRJE-UHFFFAOYSA-N cyclopropanecarbonyl chloride Chemical compound ClC(=O)C1CC1 ZOOSILUVXHVRJE-UHFFFAOYSA-N 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 238000006264 debenzylation reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-O diethylammonium Chemical compound CC[NH2+]CC HPNMFZURTQLUMO-UHFFFAOYSA-O 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 239000002988 disease modifying antirheumatic drug Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002451 electron ionisation mass spectrometry Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 229940073621 enbrel Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- XKSJMRFBVFFEHQ-SNAWJCMRSA-N ethyl (e)-3-(2-amino-4-chloro-5-methoxyphenyl)prop-2-enoate Chemical compound CCOC(=O)\C=C\C1=CC(OC)=C(Cl)C=C1N XKSJMRFBVFFEHQ-SNAWJCMRSA-N 0.000 description 1
- XBFWLXIOONPQFL-UHFFFAOYSA-N ethyl 3-tributylstannylprop-2-enoate Chemical compound CCCC[Sn](CCCC)(CCCC)C=CC(=O)OCC XBFWLXIOONPQFL-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000011737 fluorine Chemical group 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001207 fluorophenyl group Chemical group 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940048921 humira Drugs 0.000 description 1
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 1
- 229940091173 hydantoin Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
- 208000016036 idiopathic nephrotic syndrome Diseases 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229940047889 isobutyramide Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- USJUUYYGHABIBU-UHFFFAOYSA-N methanesulfonamide;hydrochloride Chemical compound Cl.CS(N)(=O)=O USJUUYYGHABIBU-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- VHCSJCFEYXNKHF-HWKANZROSA-N methyl (e)-3-(2-amino-4-chlorophenyl)prop-2-enoate Chemical compound COC(=O)\C=C\C1=CC=C(Cl)C=C1N VHCSJCFEYXNKHF-HWKANZROSA-N 0.000 description 1
- WFCOSKUHTMJGMK-SOFGYWHQSA-N methyl (e)-3-[4-chloro-2-[(2-methylpropan-2-yl)oxycarbonylamino]phenyl]prop-2-enoate Chemical compound COC(=O)\C=C\C1=CC=C(Cl)C=C1NC(=O)OC(C)(C)C WFCOSKUHTMJGMK-SOFGYWHQSA-N 0.000 description 1
- NTNUDYROPUKXNA-UHFFFAOYSA-N methyl 2-(triphenyl-$l^{5}-phosphanylidene)acetate Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC(=O)OC)C1=CC=CC=C1 NTNUDYROPUKXNA-UHFFFAOYSA-N 0.000 description 1
- DSHBGNPOIBSIOQ-UHFFFAOYSA-N methyl 4-amino-2-chlorobenzoate Chemical compound COC(=O)C1=CC=C(N)C=C1Cl DSHBGNPOIBSIOQ-UHFFFAOYSA-N 0.000 description 1
- BRWMPJAKIUAACC-UHFFFAOYSA-N methyl 4-amino-5-bromo-2-chlorobenzoate Chemical compound COC(=O)C1=CC(Br)=C(N)C=C1Cl BRWMPJAKIUAACC-UHFFFAOYSA-N 0.000 description 1
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- MIKYTWIYRCVNRL-UHFFFAOYSA-N n-(2-amino-5-chloro-4-fluorophenyl)acetamide Chemical compound CC(=O)NC1=CC(Cl)=C(F)C=C1N MIKYTWIYRCVNRL-UHFFFAOYSA-N 0.000 description 1
- UAVJYXHPMOEYMC-RMKNXTFCSA-N n-[2-[(e)-3-[3-acetyl-7-[(4-fluorophenyl)methyl]-3,7,9-triazabicyclo[3.3.1]nonan-9-yl]-3-oxoprop-1-enyl]-5-chloro-4-methoxyphenyl]acetamide Chemical compound C1=C(Cl)C(OC)=CC(\C=C\C(=O)N2C3CN(CC=4C=CC(F)=CC=4)CC2CN(C3)C(C)=O)=C1NC(C)=O UAVJYXHPMOEYMC-RMKNXTFCSA-N 0.000 description 1
- ODIUINXYFAWCAN-IZZDOVSWSA-N n-[3-chloro-6-[(e)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]octan-8-yl]-3-oxoprop-1-enyl]-2,4-dimethoxyphenyl]acetamide Chemical compound COC1=C(Cl)C(OC)=CC(\C=C\C(=O)N2C3CCC2CN(CC=2C=CC(F)=CC=2)C3)=C1NC(C)=O ODIUINXYFAWCAN-IZZDOVSWSA-N 0.000 description 1
- NOAPPTMGSUTSKV-RMKNXTFCSA-N n-[3-chloro-6-[(e)-3-[9-[(4-fluorophenyl)methyl]-3-oxa-7,9-diazabicyclo[3.3.1]nonan-7-yl]-3-oxoprop-1-enyl]-2,4-dimethoxyphenyl]acetamide Chemical compound COC1=C(Cl)C(OC)=CC(\C=C\C(=O)N2CC3COCC(N3CC=3C=CC(F)=CC=3)C2)=C1NC(C)=O NOAPPTMGSUTSKV-RMKNXTFCSA-N 0.000 description 1
- YQCSILINHFPQMK-UXBLZVDNSA-N n-[3-chloro-6-[(e)-3-[9-[(4-fluorophenyl)methyl]-3-oxa-7,9-diazabicyclo[3.3.1]nonan-7-yl]-3-oxoprop-1-enyl]-2-methoxyphenyl]acetamide Chemical compound COC1=C(Cl)C=CC(\C=C\C(=O)N2CC3COCC(N3CC=3C=CC(F)=CC=3)C2)=C1NC(C)=O YQCSILINHFPQMK-UXBLZVDNSA-N 0.000 description 1
- RPNOYURQBSHDAC-KPKJPENVSA-N n-[4-[3-(carbamoylamino)phenyl]-5-chloro-2-[(e)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]octan-8-yl]-3-oxoprop-1-enyl]phenyl]acetamide Chemical compound CC(=O)NC1=CC(Cl)=C(C=2C=C(NC(N)=O)C=CC=2)C=C1\C=C\C(=O)N1C(C2)CCC1CN2CC1=CC=C(F)C=C1 RPNOYURQBSHDAC-KPKJPENVSA-N 0.000 description 1
- UOWIEOXAKVESDC-WEVVVXLNSA-N n-[5-chloro-2-[(e)-3-[3-[(4-fluorophenyl)methyl]-3,7,9-triazabicyclo[3.3.1]nonan-9-yl]-3-oxoprop-1-enyl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC(Cl)=CC=C1\C=C\C(=O)N1C2CNCC1CN(CC=1C=CC(F)=CC=1)C2 UOWIEOXAKVESDC-WEVVVXLNSA-N 0.000 description 1
- ATGXYHCXARRPGD-BJMVGYQFSA-N n-[5-chloro-2-[(e)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]octan-8-yl]-3-oxoprop-1-enyl]-4-methoxyphenyl]methanesulfonamide Chemical compound C1=C(Cl)C(OC)=CC(\C=C\C(=O)N2C3CCC2CN(CC=2C=CC(F)=CC=2)C3)=C1NS(C)(=O)=O ATGXYHCXARRPGD-BJMVGYQFSA-N 0.000 description 1
- NUDMSUNJGUKNDN-BJMVGYQFSA-N n-[5-chloro-2-[(e)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]octan-8-yl]-3-oxoprop-1-enyl]-4-methylphenyl]-2-methoxyacetamide Chemical compound COCC(=O)NC1=CC(Cl)=C(C)C=C1\C=C\C(=O)N1C2CCC1CN(CC=1C=CC(F)=CC=1)C2 NUDMSUNJGUKNDN-BJMVGYQFSA-N 0.000 description 1
- CVPFGDMAYVQBHH-BJMVGYQFSA-N n-[5-chloro-2-[(e)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]octan-8-yl]-3-oxoprop-1-enyl]-4-methylphenyl]acetamide Chemical compound CC(=O)NC1=CC(Cl)=C(C)C=C1\C=C\C(=O)N1C2CCC1CN(CC=1C=CC(F)=CC=1)C2 CVPFGDMAYVQBHH-BJMVGYQFSA-N 0.000 description 1
- JKXHTVFFNULCOO-BJMVGYQFSA-N n-[5-chloro-2-[(e)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]octan-8-yl]-3-oxoprop-1-enyl]-4-methylphenyl]methanesulfonamide Chemical compound C1=C(Cl)C(C)=CC(\C=C\C(=O)N2C3CCC2CN(CC=2C=CC(F)=CC=2)C3)=C1NS(C)(=O)=O JKXHTVFFNULCOO-BJMVGYQFSA-N 0.000 description 1
- AJFLNTNUZILNBQ-KPKJPENVSA-N n-[5-chloro-2-[(e)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]octan-8-yl]-3-oxoprop-1-enyl]-4-pyridin-2-ylphenyl]acetamide Chemical compound CC(=O)NC1=CC(Cl)=C(C=2N=CC=CC=2)C=C1\C=C\C(=O)N1C(C2)CCC1CN2CC1=CC=C(F)C=C1 AJFLNTNUZILNBQ-KPKJPENVSA-N 0.000 description 1
- XGDMIKUQQXFEIL-IZZDOVSWSA-N n-[5-chloro-2-[(e)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]octan-8-yl]-3-oxoprop-1-enyl]-4-pyridin-3-ylphenyl]acetamide Chemical compound CC(=O)NC1=CC(Cl)=C(C=2C=NC=CC=2)C=C1\C=C\C(=O)N1C(C2)CCC1CN2CC1=CC=C(F)C=C1 XGDMIKUQQXFEIL-IZZDOVSWSA-N 0.000 description 1
- SSFDQYULGOMSMT-RMKNXTFCSA-N n-[5-chloro-2-[(e)-3-[3-[(4-fluorophenyl)methyl]-7-methyl-3,7,9-triazabicyclo[3.3.1]nonan-9-yl]-3-oxoprop-1-enyl]-4-methoxyphenyl]acetamide Chemical compound C1=C(Cl)C(OC)=CC(\C=C\C(=O)N2C3CN(C)CC2CN(CC=2C=CC(F)=CC=2)C3)=C1NC(C)=O SSFDQYULGOMSMT-RMKNXTFCSA-N 0.000 description 1
- FAGZYDDCOFJCFB-UXBLZVDNSA-N n-[5-chloro-2-[(e)-3-[3-[(4-fluorophenyl)methyl]-7-methyl-3,7,9-triazabicyclo[3.3.1]nonan-9-yl]-3-oxoprop-1-enyl]phenyl]acetamide Chemical compound C1C(N2C(=O)\C=C\C=3C(=CC(Cl)=CC=3)NC(C)=O)CN(C)CC2CN1CC1=CC=C(F)C=C1 FAGZYDDCOFJCFB-UXBLZVDNSA-N 0.000 description 1
- YBQVUSGHJJFTKA-UXBLZVDNSA-N n-[5-chloro-2-[(e)-3-[3-[(4-fluorophenyl)methyl]-7-methyl-3,7,9-triazabicyclo[3.3.1]nonan-9-yl]-3-oxoprop-1-enyl]phenyl]methanesulfonamide Chemical compound C1C(N2C(=O)\C=C\C=3C(=CC(Cl)=CC=3)NS(C)(=O)=O)CN(C)CC2CN1CC1=CC=C(F)C=C1 YBQVUSGHJJFTKA-UXBLZVDNSA-N 0.000 description 1
- UEHWRIMPCKMLPT-VMPITWQZSA-N n-[5-chloro-2-[(e)-3-[9-[(4-fluorophenyl)methyl]-3-oxa-7,9-diazabicyclo[3.3.1]nonan-7-yl]-3-oxoprop-1-enyl]-4-methoxyphenyl]methanesulfonamide Chemical compound C1=C(Cl)C(OC)=CC(\C=C\C(=O)N2CC3COCC(N3CC=3C=CC(F)=CC=3)C2)=C1NS(C)(=O)=O UEHWRIMPCKMLPT-VMPITWQZSA-N 0.000 description 1
- NUYLKDSKMMDXMT-IZZDOVSWSA-N n-[5-chloro-4-ethoxy-2-[(e)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]octan-8-yl]-3-oxoprop-1-enyl]phenyl]acetamide Chemical compound C1=C(Cl)C(OCC)=CC(\C=C\C(=O)N2C3CCC2CN(CC=2C=CC(F)=CC=2)C3)=C1NC(C)=O NUYLKDSKMMDXMT-IZZDOVSWSA-N 0.000 description 1
- JKFSRYXCSMNBTB-RUDMXATFSA-N n-[5-chloro-4-fluoro-2-[(e)-3-[3-[(4-fluorophenyl)methyl]-3,8-diazabicyclo[3.2.1]octan-8-yl]-3-oxoprop-1-enyl]phenyl]acetamide Chemical compound CC(=O)NC1=CC(Cl)=C(F)C=C1\C=C\C(=O)N1C2CCC1CN(CC=1C=CC(F)=CC=1)C2 JKFSRYXCSMNBTB-RUDMXATFSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- WGBSTIRRHNSMRN-UHFFFAOYSA-N n-tert-butylsulfamoyl chloride Chemical compound CC(C)(C)NS(Cl)(=O)=O WGBSTIRRHNSMRN-UHFFFAOYSA-N 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- AHVQYHFYQWKUKB-UHFFFAOYSA-N oxan-4-amine Chemical compound NC1CCOCC1 AHVQYHFYQWKUKB-UHFFFAOYSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- QJPQVXSHYBGQGM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QJPQVXSHYBGQGM-UHFFFAOYSA-N 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- IWELDVXSEVIIGI-UHFFFAOYSA-N piperazin-2-one Chemical compound O=C1CNCCN1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 229940116176 remicade Drugs 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 238000001896 rotating frame Overhauser effect spectroscopy Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000002884 skin cream Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-O sulfonium Chemical compound [SH3+] RWSOTUBLDIXVET-UHFFFAOYSA-O 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- LCZVKKUAUWQDPX-UHFFFAOYSA-N tert-butyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]amino]ethyl]amino]acetate Chemical compound CC(=O)OC1=CC=CC=C1CN(CC(=O)OC(C)(C)C)CCN(CC(=O)OC(C)(C)C)CC1=CC=CC=C1OC(C)=O LCZVKKUAUWQDPX-UHFFFAOYSA-N 0.000 description 1
- PVQMNBCRCMEPFN-UHFFFAOYSA-N tert-butyl 3,7,9-triazabicyclo[3.3.1]nonane-3-carboxylate Chemical compound C1NCC2CN(C(=O)OC(C)(C)C)CC1N2 PVQMNBCRCMEPFN-UHFFFAOYSA-N 0.000 description 1
- SYYVJJWPPNEPGD-UHFFFAOYSA-N tert-butyl 3-oxa-7,9-diazabicyclo[3.3.1]nonane-7-carboxylate Chemical compound C1OCC2CN(C(=O)OC(C)(C)C)CC1N2 SYYVJJWPPNEPGD-UHFFFAOYSA-N 0.000 description 1
- ALRICFWPXNHXEQ-UHFFFAOYSA-N tert-butyl 7-[(4-fluorophenyl)methyl]-3,7,9-triazabicyclo[3.3.1]nonane-3-carboxylate Chemical compound C1C(N2)CN(C(=O)OC(C)(C)C)CC2CN1CC1=CC=C(F)C=C1 ALRICFWPXNHXEQ-UHFFFAOYSA-N 0.000 description 1
- VEMVTHSYRUSLKJ-UHFFFAOYSA-N tert-butyl 7-[2-(2-acetamido-4-chlorophenoxy)acetyl]-9-[(4-fluorophenyl)methyl]-3,7,9-triazabicyclo[3.3.1]nonane-3-carboxylate Chemical compound CC(=O)NC1=CC(Cl)=CC=C1OCC(=O)N1CC(N2CC=3C=CC(F)=CC=3)CN(C(=O)OC(C)(C)C)CC2C1 VEMVTHSYRUSLKJ-UHFFFAOYSA-N 0.000 description 1
- HPNWKORERFGQGI-UHFFFAOYSA-N tert-butyl 9-[2-(2-acetamido-4-chlorophenoxy)acetyl]-7-[(4-fluorophenyl)methyl]-3,7,9-triazabicyclo[3.3.1]nonane-3-carboxylate Chemical compound CC(=O)NC1=CC(Cl)=CC=C1OCC(=O)N1C2CN(CC=3C=CC(F)=CC=3)CC1CN(C(=O)OC(C)(C)C)C2 HPNWKORERFGQGI-UHFFFAOYSA-N 0.000 description 1
- FQFILJKFZCVHNH-UHFFFAOYSA-N tert-butyl n-[3-[(5-bromo-2-chloropyrimidin-4-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(Cl)=NC=C1Br FQFILJKFZCVHNH-UHFFFAOYSA-N 0.000 description 1
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- DRDCQJADRSJFFD-UHFFFAOYSA-N tris-hydroxymethyl-methyl-ammonium Chemical class OC[N+](C)(CO)CO DRDCQJADRSJFFD-UHFFFAOYSA-N 0.000 description 1
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 208000018464 vernal keratoconjunctivitis Diseases 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0409236.7A GB0409236D0 (en) | 2004-04-26 | 2004-04-26 | Organic compounds |
| PCT/EP2005/004422 WO2005103054A2 (en) | 2004-04-26 | 2005-04-25 | Bridged piperazine and piperidine derivatives as ccri antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA06012380A true MXPA06012380A (es) | 2007-01-17 |
Family
ID=32344398
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA06012380A MXPA06012380A (es) | 2004-04-26 | 2005-04-25 | Compuestos como antagonistas de receptor de quimiocina 1 (ccr-1). |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20070196270A1 (https=) |
| EP (1) | EP1794164A2 (https=) |
| JP (1) | JP2007534678A (https=) |
| KR (2) | KR100845356B1 (https=) |
| CN (1) | CN101238131A (https=) |
| AR (1) | AR052397A1 (https=) |
| AU (1) | AU2005235724B2 (https=) |
| BR (1) | BRPI0510313A (https=) |
| CA (1) | CA2559917A1 (https=) |
| GB (1) | GB0409236D0 (https=) |
| MX (1) | MXPA06012380A (https=) |
| RU (1) | RU2383548C2 (https=) |
| TW (1) | TW200603805A (https=) |
| WO (1) | WO2005103054A2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2712211T3 (es) | 2013-06-20 | 2019-05-09 | Bayer Cropscience Ag | Derivados de arilsulfuro y arilsulfóxido acaricidas e insecticidas |
| MX368059B (es) | 2013-07-18 | 2019-09-18 | Novartis Ag | Inhibidores de autotaxina que comprenden un núcleo de anillo heteroaromático de bencil-amida cíclica. |
| CN115286637B (zh) * | 2022-08-11 | 2024-03-22 | 成都金博汇康医药科技有限公司 | 三氮杂桥环化合物及其中间体化合物、制备方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6207665B1 (en) * | 1997-06-12 | 2001-03-27 | Schering Aktiengesellschaft | Piperazine derivatives and their use as anti-inflammatory agents |
| US6818643B1 (en) * | 1999-12-08 | 2004-11-16 | Bristol-Myers Squibb Company | Neurotrophic bicyclic diamides |
| AU2001292160A1 (en) * | 2000-10-19 | 2002-04-29 | Pfizer Products Inc. | Bridged piperazine derivatives |
| UY27003A1 (es) * | 2000-11-06 | 2002-07-31 | Schering Ag | Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer |
| JPWO2002100833A1 (ja) * | 2001-06-12 | 2004-09-24 | 住友製薬株式会社 | Ｒｈｏキナーゼ阻害剤 |
| AP2005003196A0 (en) * | 2002-07-18 | 2005-03-31 | Pfizer Prod Inc | Bicyclic piperidine derivatives as antagonists of the CCR1 chemokine receptor. |
| GB0224917D0 (en) * | 2002-10-25 | 2002-12-04 | Novartis Ag | Organic compounds |
-
2004
- 2004-04-26 GB GBGB0409236.7A patent/GB0409236D0/en not_active Ceased
-
2005
- 2005-04-25 CA CA002559917A patent/CA2559917A1/en not_active Abandoned
- 2005-04-25 WO PCT/EP2005/004422 patent/WO2005103054A2/en not_active Ceased
- 2005-04-25 CN CNA2005800132391A patent/CN101238131A/zh active Pending
- 2005-04-25 JP JP2007508868A patent/JP2007534678A/ja not_active Ceased
- 2005-04-25 KR KR1020067022181A patent/KR100845356B1/ko not_active Expired - Fee Related
- 2005-04-25 BR BRPI0510313-4A patent/BRPI0510313A/pt not_active IP Right Cessation
- 2005-04-25 EP EP05737794A patent/EP1794164A2/en not_active Withdrawn
- 2005-04-25 RU RU2006141702/04A patent/RU2383548C2/ru not_active IP Right Cessation
- 2005-04-25 AU AU2005235724A patent/AU2005235724B2/en not_active Ceased
- 2005-04-25 MX MXPA06012380A patent/MXPA06012380A/es not_active Application Discontinuation
- 2005-04-25 US US10/599,819 patent/US20070196270A1/en not_active Abandoned
- 2005-04-25 KR KR1020087002184A patent/KR20080015151A/ko not_active Ceased
- 2005-04-25 AR ARP050101623A patent/AR052397A1/es unknown
- 2005-04-25 TW TW094113108A patent/TW200603805A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20080015151A (ko) | 2008-02-18 |
| US20070196270A1 (en) | 2007-08-23 |
| GB0409236D0 (en) | 2004-05-26 |
| CN101238131A (zh) | 2008-08-06 |
| KR20070014154A (ko) | 2007-01-31 |
| WO2005103054A2 (en) | 2005-11-03 |
| RU2383548C2 (ru) | 2010-03-10 |
| EP1794164A2 (en) | 2007-06-13 |
| AR052397A1 (es) | 2007-03-21 |
| AU2005235724A1 (en) | 2005-11-03 |
| BRPI0510313A (pt) | 2007-10-16 |
| CA2559917A1 (en) | 2005-11-03 |
| AU2005235724B2 (en) | 2008-10-30 |
| JP2007534678A (ja) | 2007-11-29 |
| RU2006141702A (ru) | 2008-06-10 |
| WO2005103054A3 (en) | 2007-02-08 |
| KR100845356B1 (ko) | 2008-07-09 |
| TW200603805A (en) | 2006-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2893807T3 (es) | Derivados de imidazol pentacíclicos condensados como moduladores de la actividad de TNF | |
| ES2732156T3 (es) | Derivados de pirazolopiridina como moduladores de la actividad de TNF | |
| ES2817051T3 (es) | Derivados de imidazopirimidina como moduladores de la actividad de TNF | |
| ES2735750T3 (es) | Derivados de imidazol y pirazol condensados como moduladores de la actividad de TNF | |
| ES2810774T3 (es) | Derivados de imidazopiridina como moduladores de la actividad de TNF | |
| ES2817052T3 (es) | Derivados de imidazopiridazina como moduladores de la actividad de TNF | |
| EP3596078B1 (en) | Fused pentacyclic imidazole derivatives as modulators of tnf activity | |
| CA3110767A1 (en) | Benzimidazolone derivatives, and analogues thereof, as il-17 modulators | |
| ES2809536T3 (es) | Derivados de imidazopiridina como moduladores de la actividad de TNF | |
| UA116547C2 (uk) | Біциклічні похідні | |
| TW200913990A (en) | Novel compounds 951 | |
| KR102630010B1 (ko) | Tnf의 억제제로서 유용한 트리시클릭 헤테로시클릭 화합물 | |
| BR112016011844B1 (pt) | Derivados de triazolpiridina como moduladores de atividade de tnf | |
| KR20140042814A (ko) | 신규의 헥사하이드로사이클로펜타피롤론, 헥사하이드로피롤로피롤론, 옥타하이드로피롤로피리딘온 및 옥타하이드로피리딘온 화합물 | |
| JP2012072067A (ja) | 含窒素芳香族へテロ環化合物 | |
| JP2019512534A (ja) | Ｔｎｆ活性のモジュレーターとしての縮合五環式イミダゾール誘導体 | |
| US11220489B2 (en) | Process for preparing indole carboxamide compounds | |
| MXPA06012380A (es) | Compuestos como antagonistas de receptor de quimiocina 1 (ccr-1). | |
| IL324638A (en) | Small molecule modulators of Eyal-17E, methods of making and methods of using them | |
| CA3055863C (en) | Fused pentacyclic imidazole derivatives as modulators of tnf activity | |
| WO2024251276A1 (zh) | 氧代吡啶类化合物的新型制备方法及关键中间体和应用 | |
| NZ730256B2 (en) | Fused pentacyclic imidazole derivatives | |
| NZ730256A (en) | Fused pentacyclic imidazole derivatives | |
| NZ625965A (en) | Kinase inhibitors useful as anti-inflammatory agents | |
| NZ625965B2 (en) | Kinase inhibitors useful as anti-inflammatory agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |